In patients already treated with the maximal tolerated dose of metformin at baseline and in case of severe hyperglycaemia, a different first-line approach was used: 2/26 (7.7%) were treated with glucagon-like peptide-1 (GLP-1) agonists (50% responders; 50% non-responders), 3/26 (11.5%) with insulin (33.3% responders; 66.7% non-responders), 1/26 (3.8%) with sulfonylurea (100% non-responders), whereas 4/26 (15.4%) with a combined therapy of 2/3 antidiabetic drugs (50% responders; 25% non-responders; 25% unknown for drop-out). The gene discussed is INS; the disease is Hyperglycemia.